Trial Profile
A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Abrilumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Amgen
- 08 Feb 2019 This trial has been completed in the United Kingdom, according to European Clinical Trials Database.
- 22 Nov 2018 Primary endpoint (Remission at week 8: To evaluate the effect of AMG 181 (21 mg) vs placebo on induction of remission in subjects with moderate to severe ulcerative colitis (UC) at week 8 after treatment as assessed by the total Mayo Score) has been met, as per the results published in the Gastroenterology.
- 22 Nov 2018 Primary endpoint (Remission at week 8: To evaluate the effect of AMG 181 (7 mg) vs placebo on induction of remission in subjects with moderate to severe ulcerative colitis (UC) at week 8 after treatment as assessed by the total Mayo Score) has been met, as per the results published in the Gastroenterology.